Abstract
Immune checkpoint inhibitors (ICIs) targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death 1 (PD-1) have improved overall survival (OS) in patients (pts) with advanced melanoma, and neoadjuvant ICIs can induce tumor regression in pts with resectable melanoma. Targeting other co-inhibitory receptors, such as lymphocyte activation gene-3 (LAG-3) or T cell immunoglobulin and ITIM domain (TIGIT), or combining agents targeting multiple immune evasion mechanisms may enhance antitumor activity.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Annals of oncology : official journal of the European Society for Medical Oncology
Paper Title
Journal
Date
